Sumitomo Mitsui Trust Group
CPRX

Sumitomo Mitsui Trust Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,800
Closed -$229K – 1063
2024
Q2 		$229K Sell
14,800
-11,900
-45% -$185K ﹤0.01% 1037
2024
Q1 		$426K Buy
+26,700
New +$402K ﹤0.01% 1033

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Sumitomo Mitsui Trust Group's CPRX Position: Q3 2024 in Review

Sumitomo Mitsui Trust Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 14,800 shares — an estimated $229K sold.

Sumitomo Mitsui Trust Group first reported a position in CPRX in Q1 2024 and held it in 2 quarters. The position peaked at $426K in Q1 2024. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Sumitomo Mitsui Trust Group reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 14,800 Catalyst Pharmaceutical shares in Q3 2024, an estimated $229K.
  • Sumitomo Mitsui Trust Group first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 2 quarters.
  • Sumitomo Mitsui Trust Group's Catalyst Pharmaceutical position peaked at $426K in Q1 2024.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2024, filed 5 Nov 2024.